Market Tracker

07/01 5:16pm ET

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

50.05
Delayed Data
As of 4:00pm ET
 -0.18 / -0.36%
Today’s Change
48.01
Today|||52-Week Range
72.31
-23.75%
Year-to-Date
Bargain Buys: These 3 Biopharma Stocks Are All Down Big in 2016
Jun 30 / MotleyFool.com - Paid Partner Content
Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
Jun 24 / Zacks.com - Paid Partner Content
Teva Inches Closer to Completion of Allergan Generics Deal
Jun 28 / TheStreet.com - Paid Partner Content
Impax (IPXL) Stock Declines on Deal to Buy Generic Products
Jun 22 / Zacks.com - Paid Partner Content
Teva Pharmaceuticals (TEVA) Stock Climbs on Generic Products Sale
Jun 28 / TheStreet.com - Paid Partner Content
Is Opko Health a Buy Now That Rayaldee Is Approved?
Jun 21 / MotleyFool.com - Paid Partner Content
Teva's Cinqaero Gets Positive CHMP View, Decision in 2H16
Jun 27 / Zacks.com - Paid Partner Content
Why Is Impax Labs Tumbling 11.7% Today
Jun 21 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close50.23
Today’s open50.35
Day’s range49.94 - 50.38
Volume3,799,702
Average volume (3 months)5,989,245
Market cap$51.3B
Dividend yield2.72%
Data as of 4:00pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)-48.62%
Earnings growth (this year)--
Earnings growth (next 5 years)+6.45%
Revenue growth (last year)-3.25%
P/E ratio26.1
Price/Sales2.89
Price/Book1.72

Competitors

 Today’s
change
Today’s
% change
DEPODepomed Inc+0.21+1.07%
BGNEBeiGene Ltd-0.16-0.54%
OASMOasmia Pharmaceutica...+0.05+1.45%
VBLTVascular Biogenics L...-0.21-4.56%
Data as of 4:00pm ET, 07/01/2016

Financials

Next reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$19.6B
Annual profit (last year)$1.6B
Net profit margin8.09%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President, Chief Executive Officer &
Director
Erez Vigodman
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Tel Aviv

Forecasts